Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02226146 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid
A Phase 2 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT02226146 is a Phase 2 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 11 participants.
The verdict
NCT02226146, a Phase 2 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is an open-label, proof-of-concept, single group study in adult participants with newly diagnosed, moderate to extensive BP.
Interventions
- BIOLOGICAL Bertilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-02-29 |
| Est. Completion | 2018-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02226146
The ClinicalTrials.gov registry entry for NCT02226146 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bertilimumab is the first listed.
NCT02226146 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02226146 about?
NCT02226146 is a clinical study titled "Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid". This is an open-label, proof-of-concept, single group study in adult participants with newly diagnosed, moderate to extensive BP.
What is the current status of trial NCT02226146?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2016-02-29. Estimated completion is 2018-04-30.
What interventions are being tested in trial NCT02226146?
The interventions under investigation include: Bertilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02226146?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.